Fermenta Biotech Ltd (FERMENTA) — shareholding pattern, promoter holding, financials and share price
About Fermenta Biotech Ltd (FERMENTA)
Fermenta Biotech Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as FERMENTA and on the BSE under scrip code 506414. Its ISIN is INE225B01021.
Incorporated in 1951, Fermenta Biotech Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products [1]
Fermenta Biotech Limited manufactures and supplies scientifically-validated nutritional ingredients, APIs, enzymes, and green-chemistry solutions to global pharmaceutical, nutraceutical, food, veterinary and animal feed customers, operating manufacturing sites across India and a German toll manufacturing collaboration, supported by an R&D hub and multiple global regulatory certifications.
The company posted consolidated 9M FY26 revenue of INR 421.2 crore, up 25% year‑on‑year, driven by a 51% increase in Human Vitamin D3 and a 46% rise in Animal Nutrition volumes, while Q3 showed sequential revenue improvement despite YoY moderation linked to a large one-off real estate income in the prior year.
Listed peers in Pharmaceuticals: Syncom Formulations (India) Ltd, Lincoln Pharmaceuticals Ltd, Accent Microcell Ltd, Bajaj Healthcare Ltd, Themis Medicare Ltd, Wanbury Ltd.
Valuation & Returns
10 Jul 2026At ₹409.8 a share on 10 Jul 2026, Fermenta Biotech Ltd (FERMENTA) was valued at a price-to-earnings ratio of 17.17x against an industry P/E of 36.41x and a price-to-book of 3.33x on a book value of ₹123.23 per share as of Mar 2025. Solomo computes return on equity of 19.37% and return on capital employed of 22.49% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 17.17x
- Industry P/E
- 36.41x
- P/B
- 3.33x
- EPS (TTM)
- ₹23.87
- Book value / share
- ₹123.23
- ROE
- 19.37%
- ROCE
- 22.49%
- ROA
- 11.43%
- Debt / equity
- 0.32x
- Dividend yield
- 0.61%
- EBITDA margin
- 24.57%
- 52-week range
- ₹256.4 – ₹415.7
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Fermenta Biotech Ltd (FERMENTA) reported revenue of ₹525 crore, net profit of ₹70 crore and earnings per share of ₹24.39. That compares with revenue of ₹468 crore and net profit of ₹76 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹122 crore and net profit ₹19 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 397 | 349 | 335 | 468 | 525 |
| Net profit (₹ cr) | 15 | -53 | -24 | 76 | 70 |
| EPS (₹) | 5.25 | -17.36 | -7.84 | 26.12 | 24.39 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 60.37% | 7.46% | 3.53% | 39.87% |
| Profit growth | - | 1.21% | 30.77% | 418.20% |
| Stock price CAGR | 23% | 8% | 48% | 21% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 64.09% of Fermenta Biotech Ltd (FERMENTA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.13% and domestic institutional investors (DII) hold 0.04%. Market capitalisation was ₹1,206 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Rakesh Kantilal Shah 1.76%, Krishan Premnarayen 1.38%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 64.09% | - | 0.13% | 0.04% | 33.36% |
| Mar 2026 | 64.09% | - | 0.02% | 0% | 33.33% |
| Dec 2025 | 64.09% | - | 0.02% | 0% | 34.01% |
| Sep 2025 | 64.09% | - | 0.02% | 0% | 34.78% |
| Jun 2025 | 64.09% | - | 0.02% | 0% | 35.02% |
| Mar 2025 | 64.09% | - | 0.02% | 0% | 35.02% |
| Dec 2024 | 62.06% | - | 0.02% | 0% | 37% |
| Sep 2024 | 62.06% | - | 0.05% | 0% | 36.47% |